Research & Development
EyePoint Pharmaceuticals doses first patient in phase two 'Durasert and Vorolanib in Ophthalmology 2' EYP-1901 clinical trial
2 August 2022 -

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a US-based pharmaceutical company that is focused on developing and commercialising therapeutics to improve the lives of patients with serious eye disorders, announced on Monday that it has dosed its first patient in the phase two 'Durasert and Vorolanib in Ophthalmology 2' (DAVIO 2) clinical trial of EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) to treat wet age-related macular degeneration (wet AMD).

The twelve-month, randomised, controlled Phase two DAVIO 2 trial of EYP-1901 for wet AMD is likely to enrol around 150 patients, previously treated with a standard-of-care anti-VEGF therapy, randomly assigned to one of two doses of the product (approximately 2mg or 3mg) or an aflibercept control. The product is delivered with a single intravitreal injection in the physician's office, similar to present FDA approved anti-VEGF treatments.

Nancy Lurker, EyePoint Pharmaceuticals' chief executive officer, said, 'We are very pleased to announce the initiation of the Phase 2 DAVIO 2 clinical trial of EYP-1901 for wet AMD. Using a 'Treat to Maintain' therapeutic approach, EYP-1901 has the potential to transform the wet AMD treatment landscape by sustaining a majority of patients up to six months without supplemental anti-VEGF treatment, thereby greatly reducing the treatment burden. We are encouraged by the safety and efficacy results from our Phase 1 DAVIO trial, including no reports of ocular or drug related systemic serious adverse events and strong durability data with 53 percent of patients requiring no supplemental treatment up to six months. We anticipate initial top-line data from our Phase 2 trial in the second half of 2023.'



Related Headlines